Onconova Therapeutics(US:ONTX)2025-08-14 11:01Financial Performance - Revenue for Q2 2025 was $2.7 million, a significant increase from $57 thousand in Q2 2024, attributed to deferred revenue from a licensing agreement termination[12] - Revenue for Q2 2025 reached $2.73 million, a significant increase from $57,000 in Q2 2024, representing a growth of approximately 4,684%[30] - The net loss for Q2 2025 was $0.9 million, or $0.11 per share, compared to a net loss of $123.1 million, or $20.52 per share, in Q2 2024[15] - Net loss for Q2 2025 was $915,000, compared to a net loss of $123.14 million in Q2 2024, reflecting an improvement of approximately 99.26%[30] - The company reported a net income attributable to common stockholders of $14.86 million for the first half of 2025, compared to a net loss of $34.72 million in the same period of 2024[30] Cash and Investments - Cash, cash equivalents, and short-term investments as of June 30, 2025, totaled approximately $13.1 million, down from $21.3 million as of December 31, 2024[11] - Cash and cash equivalents decreased to $13.08 million as of June 30, 2025, down from $21.34 million at the end of 2024, a decline of about 38.67%[28] - Total current liabilities decreased to $7.35 million as of June 30, 2025, from $11.53 million at the end of 2024, a reduction of approximately 36.06%[28] Research and Development - Ratutrelvir, an investigational oral protease inhibitor for COVID-19, has shown plasma drug levels maintained four times above the EC90 over a 10-day treatment period in Phase 1 studies[8] - The TXM program for bird flu and seasonal flu is in discussions for inclusion in the drug stockpiling initiative, representing significant commercial potential[4] - Rigosertib demonstrated an overall response rate of 80% in treating RDEB SCC, with complete responses in 50% of evaluable patients[13] - Research and development expenses for Q2 2025 totaled $2.3 million, down from $4.0 million in Q2 2024, primarily due to reduced oncology program expenses[14] - The company has ongoing clinical trials and regulatory plans for its product candidates, including ratutrelvir and tivoxavir marboxil, with potential market opportunities being evaluated[25] Market Opportunities - Pfizer reported $427 million in sales for PAXLOVID in Q2 2025, a 70% increase compared to the same period in the prior year[4] - The U.S. market opportunity for Ratutrelvir and TXM is estimated to be multi-billion dollar markets, driven by the ongoing need for effective antiviral treatments[17][18] - Traws Pharma is actively seeking partnerships for its legacy oncology programs, including rigosertib and narazaciclib[22] Company Strategy - Traws Pharma's accumulated deficit as of June 30, 2025, was $(628.58) million, compared to $(649.15) million at the end of 2024, indicating a reduction in the deficit of approximately 3.16%[28] - The company is focused on improving therapy options to address Long COVID and other emerging health threats, highlighting its commitment to innovation and market expansion[25] - Total operating expenses for Q2 2025 were $3.98 million, down from $123.41 million in Q2 2024, indicating a reduction of about 96.77%[30] - The weighted-average shares of common stock outstanding increased to 7,359,825 for the first half of 2025, compared to 927,084 in the first half of 2024[30]